• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

    7/25/25 6:00:00 AM ET
    $CNC
    Medical Specialities
    Health Care
    Get the next $CNC alert in real time by email

    -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) --

    ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows:

    Total revenues (in millions)

    $             48,742





    Premium and service revenues (in millions)

    $             42,467





    Health benefits ratio

    93.0 %





    SG&A expense ratio

    7.1 %





    Adjusted SG&A expense ratio (1)

    7.1 %





    GAAP diluted loss per share

    $                (0.51)





    Adjusted diluted loss per share (1)

    $                (0.16)





    Total cash flow provided by operations (in millions)

    $               1,785













    (1)

    Represents a non-GAAP financial measure. A full reconciliation of the adjusted diluted loss per share and adjusted selling, general and administrative (SG&A) expenses is shown in the Non-GAAP Financial Presentation section of this release.

    "We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory," said Chief Executive Officer of Centene, Sarah M. London. "Despite the shifting landscape, we believe that the staying power of Medicaid, Medicare and the Individual Marketplace is as strong as it has ever been. Centene has significantly fortified our platform in service of these programs over the last three years, and as we move forward, we are focused on continuing to adapt with the market to deliver meaningful value to our members, our stakeholders and our shareholders over the long term."

    Awards & Community Engagement

    • Since May, Centene and its Missouri subsidiary, Home State Health, have been supporting the St. Louis community impacted by tornadoes through donations as well as volunteer hours. In June, WellCare of Kentucky announced relief efforts to support communities impacted by the tornadoes in Eastern Kentucky. WellCare, with additional funding from the Centene Foundation, will support housing and rebuilding, disperse financial assistance, and provide basic supplies to help people recover.
    • In June, Centene was named one of Newsweek's America's Greatest Workplaces for the third consecutive year. The recognition is based on employee feedback about company culture, leadership, integrity, compensation, work-life balance, and more. In May, the Company was also named to Becker's 150 Top Places to Work in Healthcare and to Newsweek's America's Greatest Workplaces for Gen Z 2025, for the second consecutive year.
    • In May, Health Net and the Centene Foundation announced grants to expand healthcare services to underserved Californians through mobile health clinics. The investment is part of Health Net's new Mobile Outreach for Value, Equity and Sustainability (MOVES) program that targets rural or resource-limited areas and will help deliver preventative care, health education, and social services directly to neighborhoods facing barriers to traditional healthcare access.

    Membership

    The following table sets forth membership by line of business:



    June 30,



    2025



    2024

    Traditional Medicaid (1)

    11,227,400



    11,640,900

    High Acuity Medicaid (2)

    1,592,300



    1,499,000

    Total Medicaid

    12,819,700



    13,139,900

    Marketplace

    5,862,800



    4,401,300

    Individual and Commercial Group (3)

    449,700



    426,400

    Total Commercial

    6,312,500



    4,827,700

    Medicare (4)

    1,026,900



    1,138,400

    Medicare Prescription Drug Plan (PDP)

    7,845,800



    6,603,600

    Total at-risk membership

    28,004,900



    25,709,600

    TRICARE eligibles

    —



    2,768,000

    Total

    28,004,900



    28,477,600











    (1)

    Membership includes Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Children's Health Insurance Program (CHIP), Foster Care and Behavioral Health.

    (2)

    Membership includes Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals.

    (3)

    Membership includes Commercial Group, Individual Coverage Health Reimbursement Arrangement (ICHRA) and Other Off-Exchange Individual.

    (4)

    Membership includes Medicare Advantage and Medicare Supplement.

    Premium and Service Revenues

    The following table sets forth supplemental revenue information ($ in millions):





    Three Months Ended June 30,





    2025



    2024



    % Change

    Medicaid

    $           21,723



    $           20,250



    7 %

    Commercial

    10,070



    8,535



    18 %

    Medicare (1)

    9,450



    5,978



    58 %

    Other

    1,224



    1,210



    1 %

    Total premium and service revenues

    $           42,467



    $           35,973



    18 %















    (1)

    Medicare includes Medicare Advantage, Medicare Supplement and Medicare PDP.

    Statement of Operations: Three Months Ended June 30, 2025

    • For the second quarter of 2025, premium and service revenues increased 18% to $42.5 billion from $36.0 billion in the comparable period of 2024. The increase was primarily driven by premium and membership growth in the PDP business along with overall market growth in the Marketplace business, and rate increases in the Medicaid business, partially offset by lower Medicaid membership as a result of redeterminations and lower Marketplace net risk adjustment revenue. The three months ended June 30, 2024, benefited from outperformance in Marketplace risk adjustment for the 2023 benefit year.
    • Health benefits ratio (HBR) of 93.0% for the second quarter of 2025 represents an increase from 87.6% in the comparable period in 2024. The increase was primarily driven by a reduction in the Company's net 2025 Marketplace risk adjustment revenue transfer estimate, increased Marketplace medical costs, higher medical costs in Medicaid driven primarily by behavioral health, home health and high-cost drugs, and an increase to the 2025 Medicare Advantage premium deficiency reserve based on the progression of earnings during the year (with higher earnings at the beginning of the year and lower at the end of the year, given cost sharing progression).
    • The SG&A expense ratio was 7.1% for the second quarter of 2025, compared to 8.0% in the second quarter of 2024. The adjusted SG&A expense ratio was 7.1% for the second quarter of 2025, compared to 8.0% in the second quarter of 2024. The decreases were primarily driven by continued leveraging of expenses over higher revenues and growth in the PDP business. The decreases were partially offset by growth in the Marketplace business, which operates at a meaningfully higher SG&A expense ratio as compared to the overall company.
    • The income tax expense recorded in the second quarter of 2025 reflects the year-to-date impact of a lower estimated full year 2025 effective tax rate.
    • Diluted loss per share was $(0.51) for the second quarter of 2025 driven primarily by a reduction in the Company's net 2025 Marketplace risk adjustment revenue transfer estimate.
    • Cash flow provided by operations for the second quarter of 2025 was $1.8 billion, primarily driven by improved pharmacy rebate remittance timing.

    Balance Sheet

    At June 30, 2025, the Company had cash, investments and restricted deposits of $37.5 billion and maintained $234 million of cash and cash equivalents in its unregulated entities. Medical claims liabilities totaled $20.1 billion. The Company's days in claims payable (DCP) was 47 days, a decrease of two days as compared to the first quarter of 2025 driven by the timing and types of claims, as well as the impact of state-directed payments. Total debt was $17.6 billion, which included no borrowings on the $4.0 billion Revolving Credit Facility at quarter end.

    Outlook

    The Company will provide 2025 earnings expectations on the conference call.

    Conference Call

    As previously announced, the Company will host a conference call Friday, July 25, 2025, at 8:00 a.m. ET to review the financial results for the second quarter ended June 30, 2025.

    Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, under the Investors section.

    A webcast replay will be available for on-demand listening shortly following the completion of the call for the next 12 months or until 11:59 p.m. ET on Friday, July 24, 2026, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. ET on Friday, August 1, 2025, by dialing 1-877-344-7529 in the U.S., 1-855-669-9658 in Canada, or +1-412-317-0088 from abroad, and entering access code 7322068.

    Non-GAAP Financial Presentation

    The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Specifically, the Company believes the presentation of non-GAAP financial measures that excludes amortization of acquired intangible assets, acquisition and divestiture related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's core performance over time.

    The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):



    Three Months Ended June 30,



    Six Months Ended June 30,



    2025



    2024



    2025



    2024

    GAAP net earnings (loss) attributable to Centene

    $                (253)



    $              1,146



    $              1,058



    $              2,309

    Amortization of acquired intangible assets

    173



    173



    346



    346

    Acquisition and divestiture related expenses

    1



    6



    1



    67

    Other adjustments (1)

    58



    2



    61



    (97)

    Income tax effects of adjustments (2)

    (58)



    (44)



    (100)



    (126)

    Adjusted net earnings (loss)

    $                  (79)



    $              1,283



    $              1,366



    $              2,499

    ‌







    (1)

    Other adjustments include the following pre-tax items:

    ‌









    2025:









    (a)

    for the three months ended June 30, 2025: intangible asset impairment related to the wind-down of certain contracts in the Other segment of $55 million and a reduction to the previously reported gain on real estate transactions of $3 million;

    ‌











    (b)

    for the six months ended June 30, 2025: intangible asset impairment related to the wind-down of certain contracts in the Other segment of $55 million, a reduction to the previously reported gain on the sale of Magellan Rx of $10 million and a net gain on real estate transactions of $4 million.

    ‌









    2024:









    (a)

    for the three months ended June 30, 2024: gain on the previously reported divestiture of Circle Health of $10 million, an additional loss on the divestiture of our Spanish and Central European businesses of $7 million, severance costs due to a restructuring of $4 million, reduction to the net gain on the sale of property due to closing costs of $3 million and net gain on the finalization of working capital adjustments for the previously reported divestiture of Magellan Specialty Health of $2 million;

    ‌











    (b)

    for the six months ended June 30, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $83 million, net gain on the sale of property of $21 million, gain on the previously reported divestiture of Circle Health of $20 million, Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $14 million, severance costs due to a restructuring of $13 million, an additional loss on the divestiture of our Spanish and Central European businesses of $7 million and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $7 million.

    ‌







    (2)

    The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment.

    ‌









    Three Months Ended

    June 30,



    Six Months Ended

    June 30,



    2025



    2024



    2025



    2024

    GAAP diluted earnings (loss) per share attributable to Centene

    $            (0.51)



    $              2.16



    $              2.13



    $              4.32

    Amortization of acquired intangible assets

    0.35



    0.33



    0.70



    0.65

    Acquisition and divestiture related expenses

    —



    0.01



    —



    0.13

    Other adjustments (3)

    0.12



    —



    0.12



    (0.18)

    Income tax effects of adjustments (4)

    (0.12)



    (0.08)



    (0.20)



    (0.24)

    Adjusted diluted earnings (loss) per share

    $            (0.16)



    $              2.42



    $              2.75



    $              4.68

    ‌







    (3)

    Other adjustments include the following pre-tax items:

    ‌









    2025:









    (a)

    for the three months ended June 30, 2025: intangible asset impairment related to the wind-down of certain contracts in the Other segment of $0.11 per share ($0.08 after-tax) and a reduction to the previously reported gain on real estate transactions of $0.01 per share ($0.01 after-tax);

    ‌











    (b)

    for the six months ended June 30, 2025: intangible asset impairment related to the wind-down of certain contracts in the Other segment of $0.11 per share ($0.08 after-tax), a reduction to the previously reported gain on the sale of Magellan Rx of $0.02 ($0.02 after-tax) and a net gain on real estate transactions of $0.01 ($0.01 after-tax);

    ‌









    2024:









    (a)

    for the three months ended June 30, 2024: gain on the previously reported divestiture of Circle Health of $0.02 ($0.02 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.01 ($0.01 after-tax) severance costs due to a restructuring of $0.01 ($0.01 after-tax);

    ‌











    (b)

    for the six months ended June 30, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $0.15 ($0.11 after-tax), net gain on the sale of property of $0.04 ($0.03 after-tax), gain on the previously reported divestiture of Circle Health of $0.04 ($0.12 after-tax), Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $0.03 ($0.02 after-tax), severance costs due to a restructuring of $0.02 ($0.02 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.01 ($0.01 after-tax) and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $0.01 ($0.01 after-tax).

    ‌







    (4)

    The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment.

    ‌









    Three Months Ended June 30,



    Six Months Ended June 30,



    2025



    2024



    2025



    2024

    GAAP selling, general and administrative expenses

    $              3,036



    $              2,894



    $              6,389



    $              6,112

    Less:















    Acquisition and divestiture related expenses

    1



    6



    1



    67

    Restructuring costs

    —



    4



    —



    13

    Adjusted selling, general and administrative

         expenses

    $              3,035



    $              2,884



    $              6,388



    $              6,032

    To provide clarity on the way management defines certain key metrics and ratios, the Company is providing a description of how the metric or ratio is calculated as follows:

    • Health Benefits Ratio (HBR) (GAAP) = Medical costs divided by premium revenues.
    • SG&A Expense Ratio (GAAP) = Selling, general and administrative expenses divided by premium and service revenues.
    • Adjusted SG&A Expense Ratio (non-GAAP) = Adjusted selling, general and administrative expenses divided by premium and service revenues.
    • Adjusted Effective Tax Rate (non-GAAP) = GAAP income tax expense (benefit) excluding the income tax effects of adjustments to net earnings divided by adjusted earnings (loss) before income tax expense.
    • Adjusted Net Earnings (non-GAAP) = Net earnings less amortization of acquired intangible assets, less acquisition and divestiture related expenses, as well as adjustments for other items, net of the income tax effect of the adjustments.
    • Adjusted Diluted EPS (non-GAAP) = Adjusted net earnings divided by weighted average common shares outstanding on a fully diluted basis.
    • Debt to Capitalization Ratio (GAAP) = Total debt, divided by total debt plus total stockholder's equity.
    • Average Medical Claims Expense (GAAP) = Medical costs for the period divided by number of days in such period. Average medical claims expense is most often calculated for the quarterly reporting period.
    • Days in Claims Payable (GAAP) = Medical claims liabilities divided by average medical claims expense. Days in claims payable is most often calculated for the quarterly reporting period.

    In addition, the following terms are defined as follows:

    • State-directed Payments: Payments directed by a state that have minimal risk but are administered as a premium adjustment. These payments are recorded as premium revenue and medical costs at close to a 100% HBR. In many instances, the Company has little visibility to the timing of these payments until they are paid by a state.
    • Pass-through Payments: Non-risk supplemental payments from a state that the Company is required to pass through to designated contracted providers. These payments are recorded as premium tax revenue and premium tax expense.

    About Centene Corporation

    Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace.

    Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com.

    Forward-Looking Statements

    All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "guidance," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments, and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive, and other factors that may cause our or our industry's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables, and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs; rate cuts, insufficient rate changes or other payment reductions or delays by government payors affecting our government businesses; the effect of social, economic, and political conditions, geopolitical events and state and federal policies, including the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder, including the timing and terms of renewal or modification of the enhanced advance premium tax credits or program integrity initiatives that could have the effect of reducing membership or profitability of our products; unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation and tariffs; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that could impact revenue and future growth; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements in compliance with the terms of our contracts and state and federal regulations; our ability to comply with the terms of our contracts and state and federal regulations and our ability to effectively oversee our third-party vendors to comply with the terms of their contracts with us and state and federal regulations; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third-party vendors; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; changes in macroeconomic conditions, including inflation, interest rates and volatility in the financial markets; negative public perception of the Company and the managed care industry; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state, federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests and our ability to timely comply with any such changes to our contractual requirements or manage any unexpected delays in regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED BALANCE SHEETS

    (In millions, except shares in thousands and per share data in dollars)

    ‌



    June 30,

    2025



    December 31,

    2024



    (Unaudited)





    ASSETS







    Current assets:







    Cash and cash equivalents

    $                  14,513



    $                  14,063

    Premium and trade receivables

    21,552



    19,713

    Short-term investments

    2,768



    2,622

    Other current assets

    1,556



    1,601

    Total current assets

    40,389



    37,999

    Long-term investments

    18,797



    17,429

    Restricted deposits

    1,411



    1,390

    Property, software and equipment, net

    2,122



    2,067

    Goodwill

    17,558



    17,558

    Intangible assets, net

    5,010



    5,409

    Other long-term assets

    1,108



    593

    Total assets

    $                  86,395



    $                  82,445

    LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND

    STOCKHOLDERS' EQUITY







    Current liabilities:







    Medical claims liability

    $                  20,117



    $                  18,308

    Accounts payable and accrued expenses

    13,520



    13,174

    Return of premium payable

    2,442



    2,008

    Unearned revenue

    682



    661

    Current portion of long-term debt

    25



    110

    Total current liabilities

    36,786



    34,261

    Long-term debt

    17,552



    18,423

    Deferred tax liability

    651



    684

    Other long-term liabilities

    3,903



    2,567

    Total liabilities

    58,892



    55,935

    Commitments and contingencies







    Redeemable noncontrolling interests

    11



    10

    Stockholders' equity:







    Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or

         outstanding at June 30, 2025 and December 31, 2024

    —



    —

    Common stock, $0.001 par value; authorized 800,000 shares; 622,834 issued and

         491,128 outstanding at June 30, 2025, and 620,195 issued and 495,907

         outstanding at December 31, 2024

    1



    1

    Additional paid-in capital

    20,671



    20,562

    Accumulated other comprehensive (loss)

    (231)



    (504)

    Retained earnings

    16,406



    15,348

    Treasury stock, at cost (131,706 and 124,288 shares, respectively)

    (9,441)



    (8,997)

    Total Centene stockholders' equity

    27,406



    26,410

    Nonredeemable noncontrolling interest

    86



    90

    Total stockholders' equity

    27,492



    26,500

    Total liabilities, redeemable noncontrolling interests and stockholders' equity

    $                  86,395



    $                  82,445

     

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (In millions, except shares in thousands and per share data in dollars)

    (Unaudited)

    ‌



    Three Months Ended

    June 30,



    Six Months Ended

    June 30,



    2025



    2024



    2025



    2024

    Revenues:















    Premium

    $     41,740



    $     35,140



    $     83,452



    $     70,669

    Service

    727



    833



    1,504



    1,641

    Premium and service revenues

    42,467



    35,973



    84,956



    72,310

    Premium tax

    6,275



    3,863



    10,406



    7,933

    Total revenues

    48,742



    39,836



    95,362



    80,243

    Expenses:















    Medical costs

    38,808



    30,765



    75,311



    61,697

    Cost of services

    641



    680



    1,339



    1,349

    Selling, general and administrative expenses

    3,036



    2,894



    6,389



    6,112

    Depreciation expense

    141



    133



    283



    268

    Amortization of acquired intangible assets

    173



    173



    346



    346

    Premium tax expense

    6,346



    3,962



    10,563



    8,123

    Impairment

    55



    —



    55



    13

    Total operating expenses

    49,200



    38,607



    94,286



    77,908

    Earnings (loss) from operations

    (458)



    1,229



    1,076



    2,335

    Other income (expense):















    Investment and other income

    371



    463



    753



    1,008

    Interest expense

    (170)



    (176)



    (340)



    (354)

    Earnings (loss) before income tax

    (257)



    1,516



    1,489



    2,989

    Income tax expense

    2



    370



    434



    685

    Net earnings (loss)

    (259)



    1,146



    1,055



    2,304

    Loss attributable to noncontrolling interests

    6



    —



    3



    5

    Net earnings (loss) attributable to Centene Corporation

    $        (253)



    $       1,146



    $       1,058



    $       2,309

    ‌















    Net earnings (loss) per common share attributable to Centene Corporation:









    Basic earnings (loss) per common share

    $       (0.51)



    $         2.16



    $         2.14



    $         4.34

    Diluted earnings (loss) per common share

    $       (0.51)



    $         2.16



    $         2.13



    $         4.32

    ‌















    Weighted average number of common shares outstanding:













    Basic

    493,548



    529,602



    494,896



    532,385

    Diluted

    493,548



    530,755



    496,328



    534,517

     

    CENTENE CORPORATION AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In millions, unaudited)

    ‌



    Six Months Ended June

    30,



    2025



    2024

    Cash flows from operating activities:







    Net earnings

    $           1,055



    $           2,304

    Adjustments to reconcile net earnings to net cash provided by operating activities







    Depreciation and amortization

    629



    614

    Stock compensation expense

    94



    132

    Impairment

    55



    13

    Deferred income taxes

    (116)



    40

    (Gain) loss on divestitures, net

    10



    (103)

    Other adjustments, net

    16



    (11)

    Changes in assets and liabilities







       Premium and trade receivables

    (1,801)



    (1,059)

       Other assets

    (543)



    (404)

       Medical claims liabilities

    1,809



    173

       Unearned revenue

    21



    (118)

       Accounts payable and accrued expenses

    209



    (1,704)

       Other long-term liabilities

    1,857



    1,838

       Other operating activities, net

    —



    4

      Net cash provided by operating activities

    3,295



    1,719

    Cash flows from investing activities:







    Capital expenditures

    (343)



    (337)

    Purchases of investments

    (3,593)



    (3,434)

    Sales and maturities of investments

    2,508



    2,497

    Divestiture proceeds, net of divested cash

    —



    959

    Net cash (used in) investing activities

    (1,428)



    (315)

    Cash flows from financing activities:







    Proceeds from long-term debt

    750



    350

    Payments and repurchases of long-term debt

    (1,707)



    (565)

    Common stock repurchases

    (473)



    (954)

    Proceeds from common stock issuances

    18



    25

    Other financing activities, net

    (12)



    (4)

    Net cash (used in) financing activities

    (1,424)



    (1,148)

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

    —



    7

    Net increase in cash, cash equivalents and restricted cash and cash equivalents

    443



    263

    Cash, cash equivalents and restricted cash and cash equivalents, beginning of period

    14,156



    17,452

    Cash, cash equivalents and restricted cash and cash equivalents, end of period

    $         14,599



    $         17,715

    Supplemental disclosures of cash flow information:







    Interest paid

    $              320



    $              352

    Income taxes paid, net

    $              504



    $              551

    ‌







    The following table provides a reconciliation of cash, cash equivalents and restricted cash and cash equivalents reported within

    the Consolidated Balance Sheets to the totals above:



    June 30,



    2025



    2024

    Cash and cash equivalents

    $         14,513



    $         17,605

    Restricted cash and cash equivalents, included in restricted deposits

    86



    110

    Total cash, cash equivalents and restricted cash and cash equivalents

    $         14,599



    $         17,715

     

    CENTENE CORPORATION

    SUPPLEMENTAL FINANCIAL DATA

    ‌





    Q2



    Q1



    Q4



    Q3



    Q2





    2025



    2025



    2024



    2024



    2024

    MEMBERSHIP



















    Traditional Medicaid (1)

    11,227,400



    11,369,400



    11,408,100



    11,478,600



    11,640,900

    High Acuity Medicaid (2)

    1,592,300



    1,589,400



    1,595,400



    1,590,200



    1,499,000

    Total Medicaid

    12,819,700



    12,958,800



    13,003,500



    13,068,800



    13,139,900

    Marketplace

    5,862,800



    5,626,000



    4,382,100



    4,501,300



    4,401,300

    Individual and Commercial Group (3)

    449,700



    448,200



    431,400



    426,600



    426,400

    Total Commercial

    6,312,500



    6,074,200



    4,813,500



    4,927,900



    4,827,700

    Medicare (4)

    1,026,900



    1,043,200



    1,110,900



    1,129,900



    1,138,400

    Medicare PDP

    7,845,800



    7,867,800



    6,925,700



    6,766,400



    6,603,600

    Total at-risk membership

    28,004,900



    27,944,000



    25,853,600



    25,893,000



    25,709,600

    TRICARE eligibles

    —



    —



    2,747,000



    2,747,000



    2,768,000

    Total

    28,004,900



    27,944,000



    28,600,600



    28,640,000



    28,477,600

    ‌





















    (1)  Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health.

    (2)  Membership includes ABD, IDD, LTSS and MMP Duals.

    (3)  Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual.

    (4)  Membership includes Medicare Advantage and Medicare Supplement.

    ‌





















    NUMBER OF EMPLOYEES

    60,300



    60,400



    60,500



    60,700



    60,000

    ‌



    DAYS IN CLAIMS PAYABLE

    47



    49



    53



    51



    54

    ‌





















    CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)

    Regulated

    $        36,403



    $        35,922



    $        34,433



    $        35,558



    $        37,421

    Unregulated

    1,086



    1,042



    1,071



    1,154



    1,078

    Total

    $        37,489



    $        36,964



    $        35,504



    $        36,712



    $        38,499

    ‌





















    DEBT TO CAPITALIZATION

    39.0 %



    39.5 %



    41.2 %



    39.1 %



    39.1 %

     

    OPERATING RATIOS

    Three Months Ended June 30,



    Six Months Ended June 30,



    2025



    2024



    2025



    2024

    HBR

    93.0 %



    87.6 %



    90.2 %



    87.3 %

    SG&A expense ratio

    7.1 %



    8.0 %



    7.5 %



    8.5 %

    Adjusted SG&A expense ratio

    7.1 %



    8.0 %



    7.5 %



    8.3 %

     

    HBR BY PRODUCT

    Three Months Ended June 30,



    Six Months Ended June 30,





    2025



    2024



    2025



    2024

    Medicaid

    94.9 %



    92.8 %



    94.2 %



    91.8 %

    Commercial

    90.6 %



    73.4 %



    82.8 %



    73.4 %

    Medicare (5)

    90.9 %



    89.2 %



    88.6 %



    90.0 %

    ‌

















    (5)

    Medicare includes Medicare Advantage, Medicare Supplement, D-SNPs and Medicare PDP.

    MEDICAL CLAIMS LIABILITY

    The changes in medical claims liability are summarized as follows (in millions):

    Balance, June 30, 2024



    $                      18,173

    Less: Reinsurance recoverables



    58

    Balance, June 30, 2024, net



    18,115

    Incurred related to:





    Current period



    141,488

    Prior periods



    (2,221)

    Total incurred



    139,267

    Paid related to:





    Current period



    123,150

    Prior periods



    14,229

    Total paid



    137,379

    Plus: Premium deficiency reserve



    54

    Balance, June 30, 2025, net



    20,057

    Plus: Reinsurance recoverables



    60

    Balance, June 30, 2025



    $                      20,117

    Centene's claims reserving process utilizes a consistent actuarial methodology to estimate Centene's ultimate liability. Any reduction in the "Incurred related to: Prior periods" amount may be offset as Centene actuarially determines the "Incurred related to: Current period." Additionally, approximately $124 million was recorded as a reduction to premium revenues resulting from development within "Incurred related to: Prior periods" due to minimum HBR and other return of premium programs.

    The amount of the "Incurred related to: Prior periods" above represents favorable development and includes the effects of reserving under moderately adverse conditions, new markets where we use a conservative approach in setting reserves during the initial periods of operations, receipts from other third party payors related to coordination of benefits and lower medical utilization and cost trends for dates of service June 30, 2024, and prior.

    Cision View original content:https://www.prnewswire.com/news-releases/centene-corporation-reports-second-quarter-2025-results-302513712.html

    SOURCE Centene Corporation

    Get the next $CNC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CNC

    DatePrice TargetRatingAnalyst
    7/23/2025$30.00Overweight → Equal Weight
    Wells Fargo
    7/21/2025$33.00Buy → Hold
    TD Cowen
    7/16/2025$30.00Neutral → Underperform
    BofA Securities
    7/10/2025$33.00Overweight → Equal-Weight
    Morgan Stanley
    7/2/2025$45.00Buy → Neutral
    UBS
    7/2/2025$48.00Overweight → Neutral
    Analyst
    6/9/2025$70.00Overweight
    Morgan Stanley
    6/2/2025$65.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $CNC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Centene Corporation

      10-Q - CENTENE CORP (0001071739) (Filer)

      7/24/25 9:45:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CENTENE CORP (0001071739) (Filer)

      7/24/25 9:46:22 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Centene Corporation

      SCHEDULE 13G/A - CENTENE CORP (0001071739) (Subject)

      7/16/25 7:02:15 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

      -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $             48,742 Premium and service revenues (in millions) $             42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $                (0.51) Adjusted diluted loss per share (1) $                (0.16) Total cash flow provided by operations (in millions) $              

      7/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION TO HOST 2025 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL

      CALL MOVED TO 8AM ET ST. LOUIS, July 22, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 second quarter financial results at approximately 6:00 a.m. ET on Friday, July 25, 2025, and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, 

      7/22/25 8:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Meridian Health Plan of Illinois and Centene Foundation Award $1.5 Million to OSF HealthCare for New Mobile Maternity Care Unit

      Mobile Unit to Deliver Much Needed Perinatal Care for Women, Enhancing Health Equity for Patients throughout Central Illinois CHICAGO, July 16, 2025 /PRNewswire/ -- Meridian Health Plan of Illinois, Inc. (Meridian) and the Centene Foundation, the philanthropic arm of Centene Corporation (NYSE:CNC), today announced an award of $1.5 million to OSF HealthCare over three years for the expansion of its OSF OnCall Connect pregnancy and postpartum program. The grant will provide a new mobile maternity care unit to help deliver care to women who might otherwise have difficulty accessing pregnancy and postpartum support in the city of Peoria and other Central Illinois communities in Bureau, Henry, K

      7/16/25 8:58:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burdick Kenneth A was granted 556 shares, increasing direct ownership by 0.15% to 367,053 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      7/2/25 4:59:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Deveydt Wayne S was granted 602 shares, increasing direct ownership by 3% to 19,523 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      7/2/25 4:58:48 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Tanji Kenneth was granted 463 shares, increasing direct ownership by 10% to 5,145 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      7/2/25 4:58:36 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Centene downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Centene from Overweight to Equal Weight and set a new price target of $30.00

      7/23/25 7:38:36 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by TD Cowen with a new price target

      TD Cowen downgraded Centene from Buy to Hold and set a new price target of $33.00

      7/21/25 8:26:59 AM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene downgraded by BofA Securities with a new price target

      BofA Securities downgraded Centene from Neutral to Underperform and set a new price target of $30.00

      7/16/25 7:52:45 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Greco Thomas bought $1,015,750 worth of shares (17,000 units at $59.75), increasing direct ownership by 736% to 19,309 units (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/19/24 5:39:30 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Dallas H James bought $99,904 worth of shares (1,693 units at $59.01) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:34:06 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Director Blume Jessica L. bought $14,870 worth of shares (250 units at $59.48) (SEC Form 4)

      4 - CENTENE CORP (0001071739) (Issuer)

      12/17/24 7:33:56 PM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Leadership Updates

    Live Leadership Updates

    See more
    • NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO

      Board further strengthened with appointment of Mike McFarland as Director National Veterinary Associates Group ("NVA"), a leading veterinary care organization, today announced it has strengthened its Board with the appointments of Ken Burdick as Executive Chairman and Dr. James "Mike" McFarland as Director. These executives bring substantial healthcare and public company experience ahead of the company's future IPO. Burdick is a seasoned public company executive with more than 40 years of healthcare experience. He currently serves as Executive Chairman at LifeStance Health (NASDAQ:LFST), a leading U.S. provider of outpatient mental healthcare. Since joining LifeStance as Chairman and CEO

      5/7/25 2:00:00 PM ET
      $CNC
      $LFST
      Medical Specialities
      Health Care
      Medical/Nursing Services
    • CENTENE APPOINTS KENNETH Y. TANJI TO BOARD OF DIRECTORS

      ST. LOUIS, Feb. 24, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) ("the Company") announced today the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale g

      2/24/25 4:15:00 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Centene Corporation Names First President over Individual Coverage Health Reimbursement Arrangements (ICHRA) Business

      New leadership role reflects Centene's focus on ICHRA growth ST LOUIS, Jan. 9, 2025 /PRNewswire/ -- Centene Corporation ("Centene") (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, is pleased to announce that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan

      1/9/25 9:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Financials

    Live finance-specific insights

    See more
    • CENTENE CORPORATION REPORTS SECOND QUARTER 2025 RESULTS

      -- Diluted Loss Per Share of $(0.51); Adjusted Diluted Loss Per Share of $(0.16) -- ST. LOUIS, July 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the second quarter ended June 30, 2025. In summary, the 2025 second quarter results were as follows: Total revenues (in millions) $             48,742 Premium and service revenues (in millions) $             42,467 Health benefits ratio 93.0 % SG&A expense ratio 7.1 % Adjusted SG&A expense ratio (1) 7.1 % GAAP diluted loss per share $                (0.51) Adjusted diluted loss per share (1) $                (0.16) Total cash flow provided by operations (in millions) $              

      7/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION TO HOST 2025 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL

      CALL MOVED TO 8AM ET ST. LOUIS, July 22, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that it will release its 2025 second quarter financial results at approximately 6:00 a.m. ET on Friday, July 25, 2025, and host a conference call at 8:00 a.m. ET to review the results. Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 7878291 to expedite caller registration; or via a live, audio webcast on the Company's website at www.centene.com, 

      7/22/25 8:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care
    • CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

      -- Diluted EPS of $2.63; Adjusted Diluted EPS of $2.90 -- First quarter 2025 adjusted diluted EPS of $2.90, up 28% from $2.26 in the first quarter of 2024.17% year-over-year premium and service revenue growth.Membership increases of 29% in Marketplace and 22% in Medicare PDP, compared to the first quarter of 2024.Increased 2025 premium and service revenues guidance by $6.0 billion driven by outperformance in Marketplace enrollment and Medicare member retention.ST. LOUIS, April 25, 2025 /PRNewswire/ -- Centene Corporation (NYSE:CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025 first quarter results were as follows: Total

      4/25/25 6:00:00 AM ET
      $CNC
      Medical Specialities
      Health Care

    $CNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Centene Corporation

      SC 13G - CENTENE CORP (0001071739) (Subject)

      11/14/24 4:06:01 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/13/24 3:02:23 PM ET
      $CNC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centene Corporation

      SC 13G/A - CENTENE CORP (0001071739) (Subject)

      11/12/24 9:55:15 AM ET
      $CNC
      Medical Specialities
      Health Care